Actuate raises $22M to expand GSK-3β cancer trial Fierce BioTech By John Harbison|2019-05-18T15:41:14-08:00May 17, 2019|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Actuate raises $22M to expand GSK-3β cancer trial Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkXingEmail About the Author: John Harbison Related Posts
